Results 161 to 170 of about 64,876 (258)

The Role of Natural Compounds in Bladder Urothelial Carcinoma Treatment. [PDF]

Int J Mol Sci
Jiang H, Chen Y, Zeng X, Yang R, Zhang F, Zhang H, Zhang E, Wu X, Yan D, Yu C.   +9 more
europepmc   +1 more source

Regulation of drug resistance in bladder urothelial carcinoma by tumor aerobic glycolysis. [PDF]

J Transl Med
Weng C, Deng H, Yang Z, Zeng X, Xu H, Li J, Yu C.   +6 more
europepmc   +1 more source

Minimal residual disease in solid tumors: Clinical applications and future directions

Cancer, Volume 132, Issue 3, 1 February 2026.
Abstract Minimal residual disease (MRD) refers to the presence of residual cancer cells or tumor‐derived fragments that persist after treatment and remain undetectable by conventional imaging or protein‐based assays. Circulating tumor DNA (ctDNA) has emerged as a dynamic biomarker for MRD detection.
Theresa Abdo, Ahmad Alhalabi, Sacha Yaghi, Mohammad Aloran, You Li, María Herrán, Rami Tfayli, Thomas A. Samuel, Zeina Nahleh   +8 more
wiley   +1 more source

Neoadjuvant immunotherapy combined with HER2-targeted antibody-drug conjugate in bladder urothelial carcinoma: a case report. [PDF]

BMC Urol
Guo Z, Wang G.
europepmc   +1 more source

Beyond bacterial defences: the role of lysozyme in cancer

Clinical and Translational Medicine, Volume 16, Issue 2, February 2026.
Lysozyme (LYZ) is a multi‐functional secreted factor that encompasses both antibacterial and immunomodulatory functions. Emerging evidence highlights its complex role in tumour progression by directly influencing tumour cells and modulating the immune microenvironment.
Lei Wang, Qian Dong, Fuchu He, Zhiwen Gu, Aihua Sun   +4 more
wiley   +1 more source

Multivesicular body subunit 12B (MVB12B) overexpression represses proliferation and migration in bladder urothelial carcinoma. [PDF]

Transl Cancer Res
Li X, Cen C, Li R, Su Q, Mo W, Lin F.
europepmc   +1 more source

Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2) [PDF]

, 2018
et al,, Picus, Joel
core   +1 more source

Metabolic reprogramming of efferocytosis in the tumour microenvironment: From apoptotic‐cell clearance to therapeutic targeting

Clinical and Translational Medicine, Volume 16, Issue 2, February 2026.
This review systematically deconstructs the pathological efferocytic—metabolic axis in tumours, framing it as a three‐stage, self‐reinforcing cycle: from metabolite‐driven macrophage recruitment, through hijacked surface recognition, to post‐phagocytic metabolic reprogramming that locks in immunosuppression.
Qianlu Yang, Jie Yan, Qianxi Yang
wiley   +1 more source

Novel DNA methylation biomarkers in urine for non-invasive diagnosis of bladder urothelial carcinoma. [PDF]

Clin Epigenetics
Shi C, Xu J, Chen Q, Gao X, Chen L, Jin C, Yu Z, Dou X.   +7 more
europepmc   +1 more source

Bladder melanosis with concurrent urothelial carcinoma

Urology Case Reports, 2017
Susanna E. Yau, Eric J. Singer, Yue Sun, Michael H. Johnson   +3 more
openaire   +3 more sources